Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY013101-20
Application #
6682905
Study Section
Special Emphasis Panel (ZRG1-VISC (01))
Program Officer
Dudley, Peter A
Project Start
1984-08-02
Project End
2003-11-30
Budget Start
2003-02-01
Budget End
2003-11-30
Support Year
20
Fiscal Year
2003
Total Cost
$340,412
Indirect Cost

  Institution

Name
Mount Sinai School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029

  Publications

Hauswirth, William W; Li, Quihong; Raisler, Brian et al. (2004) Range of retinal diseases potentially treatable by AAV-vectored gene therapy. Novartis Found Symp 255:179-88; discussion 188-94
Mori, Keisuke; Gehlbach, Peter; Yamamoto, Satoru et al. (2002) AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43:1994-2000
Philpott, Nicola J; Gomos, Janette; Berns, Kenneth I et al. (2002) A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc Natl Acad Sci U S A 99:12381-5
Berns, K I; Meneses, P; Duvoisin, R et al. (2001) Use of recombinant angiostatin to prevent retinal neovascularization. Trans Am Clin Climatol Assoc 112:68-75; discussion 75-6
Meneses, P I; Hajjar, K A; Berns, K I et al. (2001) Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model. Gene Ther 8:646-8